For planning, Tygan enters implementation with required gene therapy patents already secured, owned, assigned, or exclusively controlled.
Gene Therapy Patent Platform
Tygan-controlled gene therapy patents from project start.
For planning, Tygan enters implementation with required gene therapy patents already secured, owned, assigned, or exclusively controlled.
Gene Therapy Patent Platform
Tygan-controlled gene therapy patents from project start.
Patent chain-of-title pack, assignment or exclusive-control evidence, IP vault, patent management office, and investor-release evidence file.
Gene therapy R&D, clinical translation, genetic medicine governance, SAHPRA pathway, ethics route, patient selection, genetic counselling, consent, long-term registry, adverse event reporting, and genomic data governance.
Manufacturing, import, or partnered production model for vectors, genetic payloads, cell-processing, or related advanced therapy materials.
Governance
Advanced therapy, costing, and partner claims require evidence before investor release.
Gene therapy is treated as a Tygan-owned or Tygan-controlled patent platform from project start. Medical pathways remain subject to clinical governance, SAHPRA, ethics, POPIA, patient consent, scientific validation, and independent legal review.